Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.

Tytuł :
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
Autorzy :
Beköz H; Division of Hematology, Department of Internal Medicine, Medical Faculty, Medipol University, Istanbul.
Karadurmuş N; Division of Medical Oncology, Department of Internal Medicine, Gulhane Research and Training Hospital, Ankara.
Paydaş S; Division of Medical Oncology, Department of Internal Medicine, Medical Faculty, Cukurova University, Adana.
Türker A; Division of Medical Oncology, Department of Internal Medicine, Medical Faculty, Hacettepe University, Ankara.
Toptaş T; Division of Hematology, Department of Internal Medicine, Medical Faculty, Marmara University, Istanbul.
Fıratlı Tuğlular T; Division of Hematology, Department of Internal Medicine, Medical Faculty, Marmara University, Istanbul.
Sönmez M; Division of Hematology,Department of Internal Medicine, Medical Faculty, Karadeniz Technical University, Trabzon.
Gülbaş Z; Division of Hematology, Anadolu Medical Center, Izmıt.
Tekgündüz E; Division of Hematology, Dr Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara.
Kaya AH; Division of Hematology, Dr Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara.
Özbalak M; Division of Internal Medicine, Bahçelievler State Hospital, İstanbul.
Taştemir N; Division of Hematology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul.
Kaynar L; Division of Hematology, Department of Internal Medicine, Medical Faculty, Erciyes University, Kayseri.
Yıldırım R; Division of Hematology, Department of Internal Medicine, Medical Faculty, Ataturk University, Erzurum.
Karadoğan I; Division of Hematology, Medstar Antalya Hospital, Antalya.
Arat M; Division of Hematology, Florence Nighthingale Hospital, Istanbul.
Pepedil Tanrıkulu F; Division of Hematology, Dr Turgut Noyan Research and Training Center, Baskent University, Adana.
Özkocaman V; Division of Hematology, Department of Internal Medicine, Medical Faculty, Uludag University, Bursa.
Abalı H; Division of Medical Oncology, Acıbadem University Medical Faculty Adana Hospital, Adana.
Turgut M; Division of Hematology, Department of Internal Medicine, Medical Faculty, Ondokuz Mayıs University, Samsun.
Kurt Yüksel M; Division of Hematology, Department of Internal Medicine, Medical Faculty, Ankara University, Ankara.
Özcan M; Division of Hematology, Department of Internal Medicine, Medical Faculty, Ankara University, Ankara.
Doğu MH; Division of Hematology, Istanbul Research and Training Hospital, Istanbul.
Kabukçu Hacıoğlu S; Division of Hematology, Department of Internal Medicine, Medical Faculty, Pamukkale University, Denizli.
Barışta I; Division of Medical Oncology, Department of Internal Medicine, Medical Faculty, Hacettepe University, Ankara.
Demirkaya M; Division of Medical Oncology, Department of Pediatrics, Medical Faculty, Uludag University, Bursa.
Köseoğlu FD; Division of Hematology, Department of Internal Medicine, Medical Faculty, Ege University, Izmir.
Toprak SK; Division of Hematology, Department of Internal Medicine, Medical Faculty, Ankara University, Ankara.
Yılmaz M; Division of Hematology, Department of Internal Medicine, Medical Faculty, Gaziantep University, Gaziantep.
Demirkürek HC; Division of Nuclear Medicine, V.K.V. American Hospital, Istanbul.
Demirkol O; Department of Nuclear Medicine, Koc University School of Medicine, İstanbul.
Ferhanoğlu B; Division of Hematology, V.K.V. American Hospital and Department of Internal Medicine, Division of Hematology, Koc University School of Medicine, Istanbul, Turkey. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2017 Oct 01; Vol. 28 (10), pp. 2496-2502.
Typ publikacji :
Journal Article; Multicenter Study
Język :
English
Imprint Name(s) :
Publication: 2020- : London : Elsevier
Original Publication: Dordrecht ; Boston : Kluwer Academic Publishers, c1990-
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Hodgkin Disease/*drug therapy
Adolescent ; Adult ; Aged ; Antineoplastic Agents/therapeutic use ; Brentuximab Vedotin ; Disease-Free Survival ; Female ; Hodgkin Disease/therapy ; Humans ; Immunoconjugates/therapeutic use ; Male ; Middle Aged ; Nivolumab ; Retrospective Studies ; Stem Cell Transplantation ; Young Adult
Contributed Indexing :
Keywords: Hodgkin lymphoma; nivolumab; programmed death 1 (PD-1) blocker; resistant/relapsed disease
Substance Nomenclature :
0 (Antibodies, Monoclonal)
0 (Antineoplastic Agents)
0 (Immunoconjugates)
31YO63LBSN (Nivolumab)
7XL5ISS668 (Brentuximab Vedotin)
Entry Date(s) :
Date Created: 20170930 Date Completed: 20180529 Latest Revision: 20200407
Update Code :
20210914
DOI :
10.1093/annonc/mdx341
PMID :
28961828
Czasopismo naukowe
Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile.
Patients and Methods: We present a retrospective analysis of 82 patients (median age: 30 years; range: 18-75) with relapsed/refractory HL treated with nivolumab in a named patient program from 24 centers throughout Turkey. The median follow-up was 7 months, and the patients had a median of 5 (2-11) previous lines of therapy. Fifty-seven (70%) and 63 (77%) had been treated by stem-cell transplantation and brentuximab vedotin, respectively.
Results: Among 75 patients evaluated after 12 weeks of nivolumab treatment, the objective response rate was 64%, with 16 complete responses (CR; 22%); after 16 weeks, it was 60%, with 16 (26%) patients achieving CR. Twenty patients underwent subsequent transplantation. Among 11 patients receiving allogeneic stem-cell transplantation, 5 had CR at the time of transplantation and are currently alive with ongoing response. At the time of analysis, 41 patients remained on nivolumab treatment. Among the patients who discontinued nivolumab, the main reason was disease progression (n = 19). The safety profile was acceptable, with only four patients requiring cessation of nivolumab due to serious adverse events (autoimmune encephalitis, pulmonary adverse event, and two cases of graft-versus-host disease aggravation). The 6-month overall and progression-free survival rates were 91.2% (95% confidence interval: 0.83-0.96) and 77.3% (0.66-0.85), respectively. Ten patients died during the follow-up; one of these was judged to be treatment-related.
Conclusions: Nivolumab represents a novel option for patients with cHL refractory to brentuximab vedotin, and may serve as a bridge to transplantation; however, it may be associated with increased toxicity.
(© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies